No connection

Search Results

BDRX vs UNH

BDRX
Biodexa Pharmaceuticals Plc
BEARISH
Price
$2.15
Market Cap
$1.8M
Sector
Healthcare
AI Confidence
95%
UNH
UnitedHealth Group Incorporated
NEUTRAL
Price
$323.48
Market Cap
$293.61B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
BDRX
--
UNH
24.43
Forward P/E
BDRX
--
UNH
16.08
P/B Ratio
BDRX
0.09
UNH
3.11
P/S Ratio
BDRX
--
UNH
0.66
EV/EBITDA
BDRX
-15012.8
UNH
16.47

Profitability

Gross Margin
BDRX
0.0%
UNH
18.53%
Operating Margin
BDRX
0.0%
UNH
0.34%
Profit Margin
BDRX
0.0%
UNH
2.69%
ROE
BDRX
-61.77%
UNH
12.54%
ROA
BDRX
-39.04%
UNH
3.9%

Growth

Revenue Growth
BDRX
--
UNH
12.3%
Earnings Growth
BDRX
--
UNH
-99.9%

Financial Health

Debt/Equity
BDRX
0.04
UNH
0.82
Current Ratio
BDRX
3.63
UNH
0.79
Quick Ratio
BDRX
3.63
UNH
0.7

Dividends

Dividend Yield
BDRX
--
UNH
2.73%
Payout Ratio
BDRX
0.0%
UNH
65.99%

AI Verdict

BDRX BEARISH

The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of 2/9, indicating severe operational and financial distress. Despite a strong current and quick ratio suggesting short-term liquidity, the company is unprofitable across all margins, with deeply negative ROE and ROA. Valuation metrics are largely undefined due to lack of earnings and revenue data, while the stock has lost nearly all value over the past year. Insider sentiment is neutral-to-weak, and there is no analyst coverage or dividend support, amplifying risk.

Strengths
Strong liquidity position with current and quick ratios of 3.63, indicating ability to cover short-term liabilities.
Low debt/equity ratio of 0.04, reflecting minimal leverage risk.
Two out of three recent quarters beat earnings estimates, showing some operational predictability.
Risks
Piotroski F-Score of 2/9 indicates very weak financial health and high risk of continued deterioration.
No Altman Z-Score available, but negative ROE (-61.77%) and ROA (-39.04%) suggest high bankruptcy risk.
Profitability metrics are entirely negative: 0% gross, operating, and profit margins.
UNH NEUTRAL

UnitedHealth Group presents a conflicted profile with a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between current price ($323.48) and defensive fair value (Graham Number: $175.91). While revenue growth remains robust at 12.3%, the company has suffered a catastrophic collapse in YoY earnings growth (-99.9%), suggesting severe short-term headwinds or one-time accounting shocks. Technical trends are currently bearish (0/100), though a recent one-month bounce and a favorable Forward P/E of 16.08 indicate analyst expectations of a recovery. The stock is currently trading at a significant premium to its intrinsic value, relying heavily on its market dominance and future earnings normalization.

Strengths
Strong consistent revenue growth (12.3% YoY)
Manageable Debt/Equity ratio of 0.82
Attractive Forward P/E (16.08) compared to current P/E (24.43)
Risks
Extreme earnings volatility (YoY Earnings Growth -99.9%)
Poor liquidity indicated by a Current Ratio of 0.79
Extremely thin operating margins (0.34%)

Compare Another Pair

BDRX vs UNH: Head-to-Head Comparison

This page compares Biodexa Pharmaceuticals Plc (BDRX) and UnitedHealth Group Incorporated (UNH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile